Brookes Pharma Marktanteilsanalyse für Juli 2026

Re-Uptol (Escitalopram) is an orally administered selective serotonin reuptake inhibitor (SSRI). The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). Re-Uptol (Escitalopram) is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine and dopamine neuronal reuptake. Re-Uptol (Escitalopram) has no or very low affinity for serotonergic (5-HT1-7) or other receptors including alpha- and beta-adrenergic, dopamine (D1-5), histamine (H1-3), muscarinic (M1-5), and benzodiazepine receptors. Re-Uptol (Escitalopram) also does not bind to, or has low affinity for, various ion channels including Na+, K+, Cl-, and Ca++ channels.